Orbimed Capital GP VII LLC

Orbimed Advisors LLC (10% owner) sold 860,123 shares for $39,014,045.60 at blended average $45.36

Orbimed Advisors LLC executed 4 separate sales totaling 860,123 shares for $39,014,045.60 on 2026-06-22, reducing its stake from 7,415,225 shares to 6,555,102 shares (an 11.6% reduction in holdings). The blended average sale price of $45.36 occurred when the stock was trading at $47.77 current price, positioning 4.4% below the 52-week high of $49.94. Across Orbimed's cross-ticker track record, prior sells averaged 30-day return of -8.3% and 90-day return of -17.2%, with a 90-day well-timed rate of 100.00%, indicating a strong historical pattern of selling before declines. The company remains unprofitable with net income of -$23,627,000.00 over its most recent full fiscal year, which provides material context for a large institutional holder's decision to reduce exposure at this scale.

Orbimed Advisors (10% owner) sells 281.4K shares at $45.02 for $12.7M; retains 7.39M shares. Stock up 49.3% in 90 days.

Orbimed Advisors, a 10% shareholder, executed 2 separate sales totaling 281,408 shares for $12,668,988.16 on 2026-06-15 at $45.02 per share, reducing its stake by 3.7% to 7,388,902 shares remaining. This represents a material but non-controlling reduction in a major holder's position while the company remains unprofitable with net income of $-23,627,000.00 for its most recent full fiscal year. Across Orbimed's cross-ticker track record, the insider's prior 15 sales showed an average 90-day return of -17.2% with a 100.00% well-timed rate, indicating a pattern of selling before downturns; however, ELVN has appreciated 49.3% over the prior 90 days and 13.2% over the past 30 days, trading within 7.6% of its 52-week high of $48.53. The sale occurs amid strong near-term price momentum in an unprofitable biotech, warranting investor attention to whether this reflects external capital needs or a divergence from Orbimed's typical well-timed exit pattern.

Orbimed Advisors LLC (Director) purchases 1,875,000 shares for $15,000,000.00 in private placement at Q32 Bio.

Orbimed Advisors LLC purchased 1,875,000 shares across 2 separate transactions on 2026-05-28, paying $8.00 per share for a total of $15,000,000.00. However, this transaction is flagged as a private placement—not a discretionary open-market purchase—and therefore should not be interpreted as an expression of insider conviction about the stock's near-term prospects. The stock currently trades at $11.66, up 131.4% over 30 days and 138.4% over 90 days, placing it 11.3% below its 52-week high of $13.15. Q32 Bio is an early-stage biotech company with zero quarterly revenue and a net loss of $7,609,000.00, typical for pre-commercial stage enterprises. The private-placement structure indicates this was a structured financing event rather than an open-market vote of confidence, limiting the signal value for momentum or directional conviction.